# DUAL Antithrombotic Therapy in Patients With AF and ACS

Study · id `cardio:ct-nct04023630` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04023630](<https://clinicaltrials.gov/study/NCT04023630>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04023630

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 4000 participants.

## Technical summary

Registry record NCT04023630. Randomized; no masking; primary purpose treatment. Start 2019-10-01 (anticipated); primary completion 2020-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 4000 participants (planned count; ClinicalTrials.gov record NCT04023630, source copy `cardio:ctgov-nct04023630-2019-07-17`, retrieved 2026-10-26)
- Planned start: 2019-10-01 (anticipated) (ClinicalTrials.gov record NCT04023630, source copy `cardio:ctgov-nct04023630-2019-07-17`, retrieved 2026-10-26)
- Primary completion: 2020-09-30 (anticipated) (ClinicalTrials.gov record NCT04023630, source copy `cardio:ctgov-nct04023630-2019-07-17`, retrieved 2026-10-26)
- Completion: 2021-09-30 (anticipated) (ClinicalTrials.gov record NCT04023630, source copy `cardio:ctgov-nct04023630-2019-07-17`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04023630-2019-07-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: DUAL Antithrombotic Therapy in Patients With AF and ACS
- Condition: Atrial Fibrillation
- Condition: Acute Coronary Syndromes
- Intervention (Drug): Rivaroxaban 15 MG Oral Tablet
- Intervention (Drug): Clopidogrel 75 Mg Oral Tablet
- Intervention (Drug): Ticagrelor 90 MG Oral Tablet
- Lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine (`cardio:org-second-affiliated-hospital-zhejiang-university-school-of-bfd3ac`)

## Provenance

Content hash: 3bc3e1681b07142af267a6723a37909cf88a6dd7a7d3e5df57ea1982e057bc3b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
